Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 164

1.

Association of Risk of Viremia, Immunosuppression, Serious Clinical Events, and Mortality With Increasing Age in Perinatally Human Immunodeficiency Virus-Infected Youth.

Neilan AM, Karalius B, Patel K, Van Dyke RB, Abzug MJ, Agwu AL, Williams PL, Purswani M, Kacanek D, Oleske JM, Burchett SK, Wiznia A, Chernoff M, Seage GR 3rd, Ciaranello AL; Pediatric HIV/AIDS Cohort Study and the International Maternal Adolescent and Pediatric AIDS Clinical Trials Network..

JAMA Pediatr. 2017 Mar 27. doi: 10.1001/jamapediatrics.2017.0141. [Epub ahead of print]

PMID:
28346597
2.

Antiretroviral therapy in HIV-infected adolescents: clinical and pharmacologic challenges.

Dobroszycki J, Lee P, Romo DL, Rosenberg MG, Wiznia A, Abadi J.

Expert Rev Clin Pharmacol. 2017 May;10(5):509-516. doi: 10.1080/17512433.2017.1301205. Epub 2017 Mar 14.

PMID:
28288535
3.

Prevalence of periodontal diseases in a multicenter cohort of perinatally HIV-infected and HIV-exposed and uninfected youth.

Ryder MI, Yao TJ, Russell JS, Moscicki AB, Shiboski CH; Pediatric HIV/AIDS Cohort Study..

J Clin Periodontol. 2017 Jan;44(1):2-12. doi: 10.1111/jcpe.12646. Epub 2016 Nov 22.

PMID:
27801947
4.

Decreased PD-1 Expression on CD8 Lymphocyte Subsets and Increase in CD8 Tscm Cells in Children with HIV Receiving Raltegravir.

Tuluc F, Spitsin S, Tustin NB, Murray JB, Tustin R 3rd, Schankel LA, Wiznia A, Nachman S, Douglas SD.

AIDS Res Hum Retroviruses. 2017 Feb;33(2):133-142. doi: 10.1089/AID.2016.0108. Epub 2016 Oct 18.

PMID:
27615375
5.

Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults.

Cressey TR, Hazra R, Wiznia A, Foca M, Jean-Philippe P, Graham B, King JR, Britto P, Carey VJ, Acosta EP, Yogev R; IMPAACT P1058A Team..

Pediatr Infect Dis J. 2016 Dec;35(12):1333-1335.

PMID:
27583590
6.

Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.

Larson KB, Cressey TR, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Gonzalez A, Britto P, Carey VJ, Acosta EP; International Maternal Pediatric and Adolescent AIDS Clinical Trial Protocol P1058A Team..

J Pediatric Infect Dis Soc. 2016 Jun;5(2):131-7. doi: 10.1093/jpids/piu142. Epub 2015 Jan 28.

PMID:
27199469
7.

Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults.

Foca M, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Britto P, Carey VJ, King J, Acosta EP, Cressey TR; IMPAACT P1058A Team..

Pediatr Infect Dis J. 2016 Sep;35(9):e271-4. doi: 10.1097/INF.0000000000001214.

PMID:
27187753
8.

Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.

Cressey TR, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Gonzalez A, Britto P, Carey VJ, Fletcher CV, Acosta EP; IMPAACT P1058A Team..

J Pediatric Infect Dis Soc. 2016 Apr 21. pii: piw017. [Epub ahead of print]

PMID:
27103489
9.

Antiretroviral Drug Resistance Among Children and Youth in the United States With Perinatal HIV.

Van Dyke RB, Patel K, Kagan RM, Karalius B, Traite S, Meyer WA 3rd, Tassiopoulos KK, Seage GR 3rd, Seybolt LM, Burchett S, Hazra R; Pediatric HIV/AIDS Cohort Study (PHACS)..

Clin Infect Dis. 2016 Jul 1;63(1):133-7. doi: 10.1093/cid/ciw213. Epub 2016 Apr 7.

PMID:
27056398
10.

Patterns and Correlates of Serostatus Disclosure to Sexual Partners by Perinatally-Infected Adolescents and Young Adults.

Weintraub A, Mellins CA, Warne P, Dolezal C, Elkington K, Bucek A, Leu CS, Bamji M, Wiznia A, Abrams EJ.

AIDS Behav. 2017 Jan;21(1):129-140. doi: 10.1007/s10461-016-1337-6.

PMID:
26874846
11.

Sexual Health Knowledge in a Sample of Perinatally HIV-infected and Perinatally-exposed Uninfected Youth.

Gromadzka O, Santamaria EK, Benavides JM, Dolezal C, Elkington KS, Leu CS, McKay M, Abrams EJ, Wiznia A, Bamji M, Ann Mellins C.

J HIV AIDS Soc Serv. 2015 Jul 1;14(3):277-293. Epub 2015 Aug 21.

12.

Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age.

Nachman S, Alvero C, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Rizk ML, Spector SA, Frenkel LM, Worrell C, Handelsman E, Wiznia A.

J Pediatric Infect Dis Soc. 2015 Dec;4(4):e76-83. doi: 10.1093/jpids/piu146. Epub 2015 Feb 7.

13.

Prevalence and Persistence of Varicella Antibodies in Previously Immunized Children and Youth With Perinatal HIV-1 Infection.

Purswani MU, Karalius B, Yao TJ, Schmid DS, Burchett SK, Siberry GK, Patel K, Van Dyke RB, Yogev R; Pediatric HIV/AIDS Cohort Study PHACS..

Clin Infect Dis. 2016 Jan 1;62(1):106-14. doi: 10.1093/cid/civ734. Epub 2015 Sep 18.

14.

Executive Functioning in Children and Adolescents With Perinatal HIV Infection.

Nichols SL, Brummel SS, Smith RA, Garvie PA, Hunter SJ, Malee KM, Kammerer BL, Wilkins ML, Rutstein R, Tassiopoulos K, Chernoff MC, Mellins CA; Pediatric HIVAIDS Cohort Study..

Pediatr Infect Dis J. 2015 Sep;34(9):969-75. doi: 10.1097/INF.0000000000000809.

15.

Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093.

Viani RM, Alvero C, Fenton T, Acosta EP, Hazra R, Townley E, Steimers D, Min S, Wiznia A; P1093 Study Team..

Pediatr Infect Dis J. 2015 Nov;34(11):1207-13. doi: 10.1097/INF.0000000000000848.

16.

Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.

Dehority W, Abadi J, Wiznia A, Viani RM.

Drugs. 2015 Sep;75(13):1483-97. doi: 10.1007/s40265-015-0446-2. Review.

PMID:
26242765
17.

Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women.

Colbers A, Best B, Schalkwijk S, Wang J, Stek A, Hidalgo Tenorio C, Hawkins D, Taylor G, Kreitchmann R, Burchett S, Haberl A, Kabeya K, van Kasteren M, Smith E, Capparelli E, Burger D, Mirochnick M; PANNA Network and the IMPAACT 1026 Study Team..

Clin Infect Dis. 2015 Nov 15;61(10):1582-9. doi: 10.1093/cid/civ587. Epub 2015 Jul 22.

18.

CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States.

Fairlie L, Karalius B, Patel K, van Dyke RB, Hazra R, Hernán MA, Siberry GK, Seage GR 3rd, Agwu A, Wiznia A; Pediatric HIV AIDS Cohort Study (PHACS), The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)..

AIDS. 2015 Oct 23;29(16):2109-19. doi: 10.1097/QAD.0000000000000809.

19.

Immunity to Measles, Mumps, and Rubella in US Children With Perinatal HIV Infection or Perinatal HIV Exposure Without Infection.

Siberry GK, Patel K, Bellini WJ, Karalius B, Purswani MU, Burchett SK, Meyer WA 3rd, Sowers SB, Ellis A, Van Dyke RB; Pediatric HIV AIDS Cohort Study (PHACS).; Pediatric HIV AIDS Cohort Study PHACS..

Clin Infect Dis. 2015 Sep 15;61(6):988-95. doi: 10.1093/cid/civ440. Epub 2015 Jun 9.

20.

Psychiatric symptoms and antiretroviral nonadherence in US youth with perinatal HIV: a longitudinal study.

Kacanek D, Angelidou K, Williams PL, Chernoff M, Gadow KD, Nachman S; International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1055 Study Team..

AIDS. 2015 Jun 19;29(10):1227-37. doi: 10.1097/QAD.0000000000000697.

Supplemental Content

Loading ...
Support Center